Royalty Pharma Acquires Royalty Rights to COPD/Asthma Treatment for $1.6 Billion July 18, 2022 AutoBot News 0 Royalty Pharma is paying $1.6 billion for the royalty rights to Trelegy Ellipta, a treatment for COPD and asthma.
